Since obesity and insulin resistance are major contributors to complications in PCOS patients, anti-diabetic agents may effectively promote insulin action, thereby promoting weight loss and improving T2DM3. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.